ARS Pharmaceuticals (SPRY) Long-Term Investments (2021 - 2022)

ARS Pharmaceuticals (SPRY) reported Long-Term Investments of $24.2 million for Q2 2022, down 44.93% sequentially from $44.0 million in Q1 2022.

ARS Pharmaceuticals (SPRY) Long-Term Investments (2021 - 2022) Analysis & Trends

ARS Pharmaceuticals (SPRY) has 2 years of Long-Term Investments data on file, last reported at $24.2 million in Q2 2022.

For the quarter ending Q2 2022, Long-Term Investments changed N/A year-over-year to $24.2 million; the trailing twelve-month figure through Jun 2022 stood at $24.2 million (changed N/A YoY), and the FY2021 full-year result was $64.8 million, changed N/A from the prior year.
Long-Term Investments slipped to $24.2 million in Q2 2022, from $44.0 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $64.8 million in Q4 2021 to a low of $24.2 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	505,194.89
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	ARS Pharmaceuticals	595.78 Mn	394.81 Mn	-	-

Download Data